Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC, Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.

PMID:
29419475
2.

Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas.

Glowa C, Peschke P, Brons S, Neels OC, Kopka K, Debus J, Karger CP.

Radiat Oncol. 2017 Nov 9;12(1):174. doi: 10.1186/s13014-017-0914-9.

3.

Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer.

Cardinale J, Martin R, Remde Y, Schäfer M, Hienzsch A, Hübner S, Zerges AM, Marx H, Hesse R, Weber K, Smits R, Hoepping A, Müller M, Neels OC, Kopka K.

Pharmaceuticals (Basel). 2017 Sep 27;10(4). pii: E77. doi: 10.3390/ph10040077.

4.

Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.

Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL.

J Nucl Med. 2017 Nov;58(11):1805-1810. doi: 10.2967/jnumed.116.189233. Epub 2017 May 4.

PMID:
28473595
5.

Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging.

Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K.

J Nucl Med. 2017 Mar;58(3):425-431. doi: 10.2967/jnumed.116.181768. Epub 2016 Oct 27.

6.

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U.

J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20.

7.

High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.

Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ.

J Med Imaging Radiat Oncol. 2012 Feb;56(1):40-7. doi: 10.1111/j.1754-9485.2011.02327.x.

PMID:
22339744
8.

Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer.

Denoyer D, Kirby L, Waldeck K, Roselt P, Neels OC, Bourdier T, Shepherd R, Katsifis A, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):703-12. doi: 10.1007/s00259-011-2017-4. Epub 2011 Dec 13.

PMID:
22160176
9.

68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy.

Hofman MS, Beauregard JM, Barber TW, Neels OC, Eu P, Hicks RJ.

J Nucl Med. 2011 Oct;52(10):1513-9. doi: 10.2967/jnumed.111.093344. Epub 2011 Sep 9.

10.

Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging.

Ma MT, Neels OC, Denoyer D, Roselt P, Karas JA, Scanlon DB, White JM, Hicks RJ, Donnelly PS.

Bioconjug Chem. 2011 Oct 19;22(10):2093-103. doi: 10.1021/bc200319q. Epub 2011 Sep 27.

PMID:
21877750
11.

Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration.

Denoyer D, Potdevin T, Roselt P, Neels OC, Kirby L, Greguric I, Katsifis A, Dorow DS, Hicks RJ.

J Nucl Med. 2011 Jan;52(1):115-22. doi: 10.2967/jnumed.110.078154. Epub 2010 Dec 13.

12.

High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance.

Denoyer D, Greguric I, Roselt P, Neels OC, Aide N, Taylor SR, Katsifis A, Dorow DS, Hicks RJ.

J Nucl Med. 2010 Mar;51(3):441-7. doi: 10.2967/jnumed.109.070060. Epub 2010 Feb 11.

13.

Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance.

Greguric I, Taylor SR, Denoyer D, Ballantyne P, Berghofer P, Roselt P, Pham TQ, Mattner F, Bourdier T, Neels OC, Dorow DS, Loc'h C, Hicks RJ, Katsifis A.

J Med Chem. 2009 Sep 10;52(17):5299-302. doi: 10.1021/jm9008423.

PMID:
19691348
14.

Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.

Neels OC, Koopmans KP, Jager PL, Vercauteren L, van Waarde A, Doorduin J, Timmer-Bosscha H, Brouwers AH, de Vries EG, Dierckx RA, Kema IP, Elsinga PH.

Cancer Res. 2008 Sep 1;68(17):7183-90. doi: 10.1158/0008-5472.CAN-08-0095.

15.

Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.

Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG.

J Clin Oncol. 2008 Mar 20;26(9):1489-95. doi: 10.1200/JCO.2007.15.1126.

PMID:
18349401
16.

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.

Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL.

Lancet Oncol. 2006 Sep;7(9):728-34.

PMID:
16945767

Supplemental Content

Loading ...
Support Center